PDCD1 and cancer: Currently, there are only four types of PD-1/PD-L1 blockers in the clinic, and it is now preferred to use immunotherapies alone or in combination therapy, for example: in one study, TMB was used to predict the effect of PD1 blocker pembrolizumb (keynote-028) on cancer.